INTRODUCTION {#S1}
============

Breast cancer is the most common cancer and the second leading cause of cancer death in women in the United States, with an annual incidence of 207,000 breast cancer cases in 2010 ([@R1]). Developing novel treatment strategies and targeted therapy for cancer has relied on characterizing tumors for expression of genes that influence sensitivity to specific drugs or treatments. The different clinical phenotypes of breast cancer have defined patterns of gene expression, which are predictive of recurrence and overall survival ([@R2]). Luminal A breast cancers have the best prognosis and are characterized by expression of estrogen receptor-alpha (ERα) and non-amplified expression of ErbB2/Her2. Luminal B breast cancers, which demonstrate a greater tendency to recur, also express ERα and commonly have amplified expression of ErbB2/Her2. The HER2 phenotype has low or absent expression of the steroid receptors, ERα and progesterone receptor (PgR), and amplified expression of ErbB2/Her2. The basal or "triple-negative" phenotype carries the worst prognosis and is characterized by a relatively undifferentiated cell lacking expression of the steroid receptors and ErbB2/Her2. The characteristic patterns of gene expression, in particular ERα, PgR and ErbB2/Her2, have important implications for outcome in breast cancer and further predict sensitivity to certain therapies, such as anti-estrogens and trastuzumab ([@R3]). However, we are only now beginning to define the transcriptional mechanisms that establish the patterns of expression characteristic of the various clinical phenotypes of breast cancer.

TFAP2C is a member of the retinoic acid-inducible, developmentally regulated family of AP-2 transcription factors that include five members---TFAP2A (AP-2α), TFAP2B (AP-2β), TFAP2C (AP-2γ), TFAP2D (AP-2δ) and TFAP2E (AP-2ε) ([@R4]--[@R8]). AP-2 factors bind to GC-rich regulatory elements in the promoters of target genes through a helix-loop-helix motif in the DNA binding domain, which, except for TFAP2D, is highly homologous in all the AP-2 family members ([@R9]). Interestingly, AP-2 factors have been implicated in the regulation of ERα and Her2 expression in breast cancer. TFAP2C regulates expression of ERα and several pathways of hormone response ([@R10], [@R11]) and recent findings demonstrated significant overlap in the promoters targeted by ERα and TFAP2C ([@R12]). In addition, TFAP2A and TFAP2C were able to induce expression of the cloned *ERBB2* gene promoter ([@R5], [@R13]--[@R15]). Similarly in MDA-MB-453 cells, TFAP2C was found to target the *ERBB2* promoter and knock down of TFAP2C significantly reduced ErbB2/Her2 expression ([@R16]). In BT474 breast carcinoma cells, both TFAP2A and TFAP2C were shown to participate in the regulation of ErbB2/Her2 expression ([@R17]). Furthermore, a correlation has been reported between AP-2 expression and the expression of ErbB2/Her2 in primary breast cancers ([@R17]--[@R19]). Hence, there is mounting evidence that AP-2 factors, and in particular TFAP2C, plays a central role in the regulation of genes known to have important prognostic significance in breast cancer.

By using a combination of gene expression arrays and chromatin immunoprecipitation with direct sequencing (ChIP-seq), we previously defined a set of target genes directly regulated by TFAP2C in MCF-7 breast carcinoma cells ([@R20]). Many of the TFAP2C target genes identified were known to be expressed as part of the luminal A breast cancer gene expression signature and/or part of the estrogen-regulated pathways. Notably, we found no evidence for TFAP2C binding to the *ERBB2* gene in MCF-7 cells despite other studies demonstrating that the *ERBB2* gene is regulated by TFAP2C in cells that overexpress ErbB2/Her2. This finding led to the hypothesis that TFAP2C can be directed to a different set of genes in breast cancers of different phenotypes. This hypothesis was further supported by studies of the *ERα* gene promoter showing that epigenetic chromatin modifications, including CpG methylation and histone deacetylation, was associated with chromatin inaccessibility, which blocked TFAP2C from binding to the AP-2 regulatory region in ERα-negative cells ([@R21]). Since TFAP2C is known to regulate the expression of many genes that comprise the luminal phenotype expression signature, we further hypothesized that genes differentially targeted by TFAP2C comparing breast cancer cell lines having different phenotypic expression profiles would likely identify regulatory regions of genes with a clinically significant impact. The goal of this study was to compare ChIP-seq data for TFAP2C in a panel of breast cancer cell lines representing the luminal A, luminal B and HER2 breast cancer phenotypes. We sought to identify genes with clear differences in the ability of TFAP2C to bind to the regulatory region comparing the different cell lines and to determine the molecular basis for differential gene targeting. In this way, we hoped to more fully understand the role of TFAP2C in regulating the expression of genes that impact the clinically significant breast cancer phenotypes.

RESULTS {#S2}
=======

GPX1 Promoter is Targeted by TFAP2C in Breast Cancer Cell Lines {#S3}
---------------------------------------------------------------

Previous studies identified an important role for TFAP2C in establishing patterns of gene expression that are highly predictive of the clinical phenotype in breast cancer. There was also the suggestion that important differences may exist in the genes targeted by TFAP2C comparing breast cancer cells from different phenotypes. We hypothesized that comparing different breast cancer cell lines for TFAP2C target genes could identify genes regulated by TFAP2C that play a critical role in determining clinically-relevant phenotypic differences. We chose to compare four breast cancer cell lines representing the luminal and HER2 cancer phenotypes ([@R22]). MCF-7 is an accepted model for the luminal A breast cancer phenotype, expressing ERα, non-amplified expression of HER2, TFAP2C and relatively low expression of TFAP2A (see [Figure 1a](#F1){ref-type="fig"}). BT-474 expresses ERα and HER2 and is a model for the luminal B phenotype. The relatively high level of TFAP2C expression in BT-474 is consistent with the overexpression of TFAP2C noted in more aggressive ERα-positive cancers. Based on the expression pattern for ERα and HER2, MDA-MB-453 and SKBR-3 would be classified as the HER2 breast cancer phenotype; however, the expression pattern in these cell lines suggest a luminal origin. Since all four cell lines express endogenous TFAP2C, we performed ChIP-seq using anti-TFAP2C antibody without needing to overexpress the factor. Examples of the ChIP-seq data from the four breast cancer cell lines are shown in [Figure 1B](#F1){ref-type="fig"}, which illustrates the high quality and reproducibility of the data. The data for the genomic regions from two genes---*KRT8* and *GPX1*---are presented demonstrating the cell type-specificity for TFAP2C binding at these two loci. In the first panel, a region of approximately 15 kbp is shown from the *cytokeratin 8* (*KRT8*) gene and in this diagram, transcription for *KRT8* reads right to left. The TFAP2C binding pattern is similar to what is found in most target genes---the pattern is identical for all four cell lines, there is a series of peaks clustered in and around the transcriptional start site and an additional peak within 1 kbp of the last exon. *KRT8* is one of the core genes representing the luminal cytokeratin cluster signature. We analyzed the ChIP-seq data to identify promoters that demonstrated differential targeting of TFAP2C comparing the different breast cancer phenotypes. One gene identified in this analysis was *glutathione peroxidase* (*GPX1)*, which encodes a selenoenzyme in the glutathione peroxidase family that detoxifies peroxide and is a key antioxidant in humans, protecting cells from reactive oxygen species (ROS). As seen in [Figure 1B](#F1){ref-type="fig"}, TFAP2C binds strongly to a region just upstream of the transcriptional start site (TSS) for the *GPX1* gene in BT-474 and MDA-MB-453 cell lines but there is no binding to this genomic region in MCF-7 or SKBR-3 cell lines. Interestingly, the expression pattern of GPX1 is highly variable in primary breast cancer tumors, as noted in [Figure 1C](#F1){ref-type="fig"}. These data indicate that *GPX1* is differentially targeted by TFAP2C comparing the four cell lines, thus further experiments were designed to demonstrate the functional role of TFAP2C in regulation of *GPX1* and the molecular basis for differential gene targeting.

TFAP2C Regulates Expression of GPX1 {#S4}
-----------------------------------

We evaluated GPX1 RNA and protein expression in the four breast carcinoma lines. As shown in [Figure 2A](#F2){ref-type="fig"}, *GPX1* was expressed in BT-474 and MDA-MB-453 cell lines but the gene was essentially not expressed in MCF-7 or SKBR-3. TFAP2C and TFAP2A were knocked down using siRNAs that we have previously shown to specifically knockdown each family member ([@R11]). Knockdown of TFAP2C in BT-474 or MDA-MB-453 cells reduced GPX1 expression to 50--80%, whereas knockdown of TFAP2A had no significant effect on GPX1 expression ([Figure 2B](#F2){ref-type="fig"}). Knockdown of either TFAP2C or TFAP2A had no effect on GPX1 expression in either MCF-7 or SKBR-3 (data not shown). The span of the TFAP2C peak from ChIP-seq shown in [Figure 1B](#F1){ref-type="fig"} is approximately 200 bp. Using gel-shift analyses we refined the location of TFAP2C binding in the *GPX1* promoter and a representative experiment is shown in [Figure 2C,D](#F2){ref-type="fig"}. A 60 bp region of DNA from the *GPX1* promoter centered at the ChIP-seq binding peak is shown in [Figure 2C](#F2){ref-type="fig"}. This 60 bp sequence was used as a double-stranded DNA probe, which was labeled and used in gel-shift with TnT-synthesized TFAP2C. Competitors 5, 6 and 7 were 20 bp oligos from the left, middle or right-hand region spanning the 60 bp probe. As seen in [Figure 2D](#F2){ref-type="fig"}, oligo 7 effectively competed for TFAP2C binding and the supershift with anti-TFAP2C antibody confirmed the identity of the TFAP2C complex. The sequence contained in oligo 7, 5′-CCCGGAGGG, matches the consensus site we reported for *in vitro* and genomic binding of TFAP2C ([@R20]), and the location of the site corresponds to the center of the peak from the ChIP-seq results. A second site matching the known AP-2 consensus sequence (GCCTGAGGG) was noted at the 3′ edge of oligo 5; however, since AP-2 binds poorly to oligos when the site is on the end, a modified oligo called 5\* was created that was shifted by four bp to place the potential AP-2 site into the middle of the 20 bp oligo. As seen in [Figure 2D](#F2){ref-type="fig"}, the 5\* oligo competitor also competed for TFAP2C binding to the full-length probe. These data demonstrated that *GPX1* is a TFAP2C target gene and there are two AP-2 binding sites that are targeted by TFAP2C in the *GPX1* 5′ regulatory region. In addition, the location of TFAP2C binding determined by ChIP-seq correctly predicted differential expression in these luminal breast cancer cell lines.

GPX1 Expression and Sensitivity to Oxidative Stressors {#S5}
------------------------------------------------------

The differential expression of GPX1 suggests that TFAP2C has the potential of influencing the oxidative state and sensitivity to peroxide of breast cancer cells. The selenium-dependent glutathione peroxidase activity was measured in the four breast cancer cell lines. As seen in [Figure 3A](#F3){ref-type="fig"}, relatively high levels of selenium-dependent GPX activity was found in BT-474 and MDA-MB-453 compared to minimal activity for MCF-7 and SKBR-3. These data demonstrate that GPX enzymatic activity correlates with the expression of GPX1 in the four cell lines. The functional effects of TFAP2C regulation of GPX1 was evaluated by comparing sensitivity of BT-474 to tert-butyl hydroperoxide with and without TFAP2C knock down. As seen in [Figure 3B](#F3){ref-type="fig"}, knock down of TFAP2C increased sensitivity to tert-butyl hydroperoxide over a concentration range of 20 to 60 μM compared to NT siRNA. To further prove that these differences were due to GPX1, overexpression of exogenous GPX1 was induced in MCF-7 cells by an adenoviral vector expressing the *GPX1* gene ([Figure 3C](#F3){ref-type="fig"}). Expression of GPX1 was confirmed by Western blot and resulted in an increase in selenium-dependent GPX activity. Interestingly, overexpression of TFAP2C failed to alter GPX1 expression or induce selenium-dependent GPX activity in GPX1 negative MCF-7 cells. Next, we examined whether expression of GPX1 in MCF-7 cells altered the sensitivity to tert-butyl hydroperoxide ([Figure 3D](#F3){ref-type="fig"}). MCF-7 cells induced with either Ad-empty, Ad-TFAP2C or mock infected had equal sensitivity to tert-butyl hydroperoxide with a LD50 of approximately 40 μM. However, with overexpression of GPX1, MCF-7 cells exhibited resistance to tert-butyl hydroperoxide with an LD50 that exceeded 105 μM. The data indicate an important role for TFAP2C in regulating the oxidative state and sensitivity to peroxides, particularly lipid peroxides, of breast cancer cells through the regulation of GPX1.

TFAP2C Binding to GPX1 Promoter Regulated by CpG Methylation {#S6}
------------------------------------------------------------

The next critical issue to address was the molecular basis for the lack of TFAP2C binding to the regulatory region of *GPX1* in MCF-7 and SKBR-3 breast cancer cell lines. The promoter region including the AP-2 regulatory region is GC rich and contains a number of potential DNA methylation sites. In addition, a recent study identified gene silencing of *GPX1* in gastric cancers due to CpG methylation ([@R23]). To examine CpG methylation, we used bisulfite sequencing of the *GPX1* promoter from the four cell lines and found evidence for extensive methylation of the CpGs in MCF-7 and SKBR-3 and little or no methylation of this region in BT-474 and MDA-MB-453 cells ([Figure 4A,B](#F4){ref-type="fig"}). These findings suggest that the lack of TFAP2C binding in the *GPX1* promoter identified in MCF-7 and SKBR-3 may be functionally related to DNA methylation in and around the AP-2 regulatory region. To further determine whether CpG methylation regulates TAP2C expression of GPX1, the four breast cancer cells were treated with 5-aza-2-deoxycytidine (5-aza dC) and expression of GPX1 mRNA and protein was examined. Treatment with 5-aza dC activated GPX1 expression (both GPX1 RNA and protein) in MCF-7 and SKBR-3 but had no effect on expression in BT-474 or MDA-MB-453 cell lines ([Figure 4C](#F4){ref-type="fig"}). Furthermore, treating MCF-7 cells with 5-aza-dC induced binding of TFAP2C to the *GPX1* promoter, whereas, no binding was detected in mock-treated cells ([Figure 4D](#F4){ref-type="fig"}). These data support a model in which the promoter regions of certain genes, in this case *GPX1*, are epigenetically silenced through chromatin modifications that includes DNA methylation and are insensitive to reactivation by overexpression of a transcriptional regulatory factor alone. In addition, the data demonstrate that CpG methylation is functionally linked to gene silencing since GPX1 expression was activated by 5-aza-dC drug treatment.

TFAP2C Regulates GPX1 Expression in Primary Breast Cancers {#S7}
----------------------------------------------------------

The results from cell lines indicate an important role for TFAP2C in regulating GPX1 expression in breast cancer. To determine if the cell line model mirrors regulation in primary cancers, a panel of primary breast cancer samples was analyzed for GPX1 expression and methylation of the *GPX1* promoter (see [Figure 5](#F5){ref-type="fig"}). DNA was extracted from archival breast cancer samples and subjected to analysis for CpG methylation at the *GPX1* promoter using bisulfite DNA sequencing. Representative data for CpG methylation is shown in [Figure 5A](#F5){ref-type="fig"}. Significant methylation in the region of the AP-2 regulatory regions was identified in approximately 20% of breast cancer samples. Expression of GPX1, TFAP2A and TFAP2C mRNA levels were determined using quantitative RT-PCR analysis. As shown in [Figure 5B](#F5){ref-type="fig"}, no significant association was seen comparing GPX1 and TFAP2A expression. However, a highly significant correlation was demonstrated between GPX1 and TFAP2C expression, when considering samples with an unmethylated *GPX1* promoter. Of note, one sample with high TFAP2C expression but low GPX1 expression was noted to have a methylated *GPX1* promoter (tumor 3). The correlation between expression of GPX1 and TFAP2C had an R^2^ value of 0.91 (p\<0.0001), which indicates that TFAP2C is a key factor in regulating the expression of GPX1 in breast cancers that have an unmethylated *GPX1* promoter. However, with methylation of the *GPX1* promoter, GPX1 expression is insensitive to TFAP2C transcriptional activity.

DISCUSSION {#S8}
==========

There is growing evidence that oxidative stress plays a critical role in oncogenesis and cancer progression ([@R24], [@R25]). Elevated levels of oxidative stress result in accumulation of reactive oxygen species (ROS) including superoxide, hydrogen peroxide and hydroxyl radicals. Elevated levels of ROS identified in cancer cells may result from several mechanisms including increased rates of metabolism, mitochondrial dysfunction or alteration in other enzymes in the ROS metabolic pathways. Since oxygen radicals can damage DNA, elevated ROS may play an important role in oncogenesis by contributing to genetic instability leading to transformation and cancer progression. Alternatively, increased ROS can induce a proliferative response through activation of several proliferative mechanisms including activation of the mitogen-activated protein kinases (MAPKs)/ERK1/2, increased signaling via phosphoinositide-3-kinase (PI3K)/Akt or activation of the NF-κB pathway. Alternatively, elevated levels of ROS can alter apoptotic signaling through the activation of c-Jun N-terminal kinases (JNKs), p53 or the forkhead transcription factors such as FOXO3a. Elevated levels of ROS have further been shown to be involved in metastasis by altering cell motility, cell adhesion and angiogenesis. On the other hand, elevated levels of ROS in cancer cells can also increase their susceptible to chemotherapeutic agents that are capable of increasing intracellular levels of ROS and peroxide ([@R26], [@R27]). Targeting the ROS system for cancer therapy is particularly attractive since novel chemotherapeutic agents have recently been developed that increase ROS and induce apoptosis in cancer cells with minimal effects on normal cells ([@R28]). Hence, mechanisms that modulate ROS in cancer cells influence several processes in oncogenesis and potentially offer a number of pathways for the development of novel treatment strategies.

GPX1 is an important antioxidant selenoenzyme that catalyzes the detoxification of hydrogen peroxide, resulting in the oxidation of glutathione (GSH) to glutathione disulphide (GSSG) ([@R25]). Mice genetically engineered to have a *GPX1*-null phenotype demonstrate increased liver peroxides, increased rates of hydrogen peroxide production and display growth retardation ([@R29]). Several studies have implicated an important role of GPX1 in breast cancer oncogenesis and progression. Individuals homozygous for a leucine at codon 198 of the GPX1 protein had an odds ratio for breast cancer risk that was approximately doubled compared to individuals inheriting a *GPX1* polymorphism with a proline at this position ([@R30], [@R31]). Additional studies suggested that the increased breast cancer risk associated with the Pro198Leu *GPX1* polymorphism might be further influenced by racial effects, inheritance of certain MnSOD polymorphisms, and environmental factors ([@R32]--[@R34]). Loss of heterozygosity (LOH) for the *GPX1* locus has been reported to occur in 36% of breast cancers and 42% of colon carcinomas, suggesting that elimination of GPX1 activity has oncogenic effects ([@R30], [@R35]). Finally, the expression of GPX1 in breast cancer was reported to be inversely associated with expression of ERα and was also predictive of cancer survival ([@R36], [@R37]).

Particularly germane to breast cancer treatment, GPX1 activity has been directly implicated in sensitivity to chemotherapy. Overexpression of GPX1 in T47D breast carcinoma cells significantly increased their resistance to the anthracycline, doxorubicin ([@R38]). Drugs such as docosahexaenoic acid (DHA) have been shown to enhance the effectiveness of anthracyclines by blocking GPX1 activity ([@R39]). In a cardiomyocyte model, GPX1 deficiency resulted in increased susceptibility to ROS-mediated doxorubicin-induced cardiotoxicity compared to cardiomyocytes with wild-type GPX1 expression ([@R40]). Futhermore, β-phenylethyl isothiocyanate (PEITC) was described as a novel chemotherapeutic agent, which increases ROS-mediated cell killing through inactivation of GPX1, and highlights the important role of GPX1 in regulating ROS in transformed cells and the potential for targeting GPX1 to alter chemosensitivity of cancer cells ([@R41]). GPX1 may also influence the survival of metastatic lesions. Using an animal model of breast cancer, a recent report demonstrated that tumor entrained neutrophils (TENs) inhibit lung metastases through a peroxide-mediated cell killing mechanism ([@R42]). The expression of GPX1 in some breast tumors has the potential to protect metastatic cancer cells from TEN-mediated cell killing by detoxifying peroxide.

The current findings are significant in that they demonstrate an important role for TFAP2C in regulating ROS and sensitivity to peroxide in breast cancer through the control of GPX1 expression. The results from an examination of clinical samples indicate that GPX1 regulation in primary breast cancer is complex involving both *trans*-activation through an AP-2 regulatory region and epigenetic chromatin modification through CpG methylation. Furthermore, our data indicates a unique role for TFAP2C regulation of GPX1 compared to the related family member, TFAP2A. A recent study reported that interference with AP-2 expression in a murine breast cancer cell line increased apoptosis and augmented sensitivity to doxorubicin chemotherapy ([@R43]). Although GPX1 was not directly investigated in that study, the effects of TFAP2C in mediating ROS and sensitivity to anthracyclines through GPX1 could account for the effects of AP-2 in mediating anthracycline sensitivity. Additionally, AP-2 factors may alter ROS in cancer cells through the regulation of c-myc and MnSOD ([@R44], [@R45]). Previous studies demonstrated that p53 increases oxidative stress and apoptosis through the regulation of GPX1 expression ([@R46]) and the current findings add to the growing literature suggesting important co-regulatory mechanisms involving a cooperative association of p53 and AP-2 factors ([@R47]--[@R49]).

In addition to TFAP2C induction of the *GPX1* promoter through a direct interaction with the regulatory site, activation of the *GPX1* promoter is subject to epigenetic modifications. We have previously demonstrated that chromatin modifications involving DNA methylation and histone deacetylation can make the *ERα* promoter inaccessible to TFAP2C ([@R21]). The current data expand the role for epigenetic chromatin modification of TFAP2C target genes, characterized by CpG methylation in and around the AP-2 regulatory binding site, resulting in inaccessibility of the promoter to TFAP2C. CpG methylation of the AP-2 regulatory region was proven to be functionally linked to expression by showing that treatment with drugs that inhibit DNA methylation (5-aza-dC) can re-activate expression of GPX1. Studies examining methylation of the *GPX1* promoter in gastric cancer estimated that 17% of tumors had significant promoter methylation ([@R23]); our data suggests that approximately 20% of breast cancers lack GPX1 expression due to promoter methylation. Of particular significance is that discordant expression of TFAP2C and GPX1 was identified in tumors with methylation of the *GPX1* promoter. This finding highlights the concern that failure to consider epigenetic modifications or other potential complexities in gene regulation may frustrate the ability to define transcriptional mechanisms that establish clinically relevant patterns in gene regulation.

Several important conclusions can be drawn from the findings in the current study. The first is that the results highlight the important role of TFAP2C in regulating genes that establish the clinically relevant breast cancer phenotype. The approach of comparing cell lines for differences in genomic targeting of TFAP2C has been a fruitful means of identifying critical regulatory regions of genes that influence the clinical phenotype of breast cancers. All of the cell lines utilized in the current study are of luminal origin, hence, our data does not directly address whether TFAP2C-mediated regulation of GPX1 is specific to luminal breast cancer or whether other mechanisms of gene regulation play a role in GPX1 expression in the basal (triple-negative) phenotype. However, it has been shown that GPX1 expression is found as a characteristic of basal cancer lines ([@R50]). Additional studies examining the pattern of genomic binding of TFAP2C in various cell lines, particularly cell lines of different clinical phenotype, should be an ongoing means to define the regulatory regions of key breast cancer genes. Demonstrating that TFAP2C can regulate the oxidative state and sensitivity to peroxides in breast cancer cells through the control of GPX1 provides evidence that TFAP2C likely has substantial influence over several processes critical to the biology of breast cancer including oncogenesis, sensitivity to certain chemotherapeutic agents and progression of metastases. Further work to examine directly the role of TFAP2C in these various physiologic processes will help to elucidate the biologic role of TFAP2 in cancer development and progression.

MATERIAL AND METHODS {#S9}
====================

Chromatin Immunoprecipitation with Direct Sequencing (ChIP-Seq) {#S10}
---------------------------------------------------------------

All manipulations were done as previously described ([@R20]). The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus ([@R51]) and are accessible through GEO Series accession number GSE36351 and are accessible for review through the following link: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=tvmxvweeggmmafm&acc=GSE36351>

Cell lines and tissue samples {#S11}
-----------------------------

Cell lines, MCF-7, BT-474, MDA-MB-453 and SKBR-3 were obtained from American Type Culture Collection. All cell lines were grown in appropriate medium at 37 °C in a humidified 5% CO~2~ incubator. Breast cancer tissue specimens were obtained from patient samples from surgical resection specimens under an IRB approved protocol.

RNA isolation, cDNA synthesis and Real-Time-PCR {#S12}
-----------------------------------------------

Total RNA was isolated from cell lines and breast tissue samples using Rneasy Mini Kit (Qiagen). cDNA was synthesized from 1 μg of total RNA with d(N)6 primer using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression was monitored by quantitative real-time PCR. TaqMan primers and detection probes for genes were GPX1 Assay Hs00829989_gH and TFAP2C Assay Hs00231476_m1 (Apply Biosystems). Expression values were normalized to the mean of 18S rRNA 4319413E-0803037 (Applied Biosystems) as endogenous control.

DNA isolation and sodium bisulfite modification {#S13}
-----------------------------------------------

Genomic DNA was isolated from cells and tissues using QIAamp DNA Mini kit (Qiagen). The bisulfite conversion and cleanup of DNA for methylation analysis was performed by EpiTect Bisulfite Kit (Qiagen). The EpiTect Whole Bisulfitome Kit (Qiagen) was used for amplify bisulfite converted DNA that was used for subsequent assays.

Western blots {#S14}
-------------

Western blots were done using the following primary antibodies: TFAP2-α 3B5, TFAP2-γ 6E4/4, GPDH 6C5 (Santa Cruz Biotechnology) and GPX1 3120-1 (Epitomics).

Transient transfection {#S15}
----------------------

Transfections with siRNA for TFAP2A and TFAP2C were performed as described ([@R11]). Non-targeting siRNA was obtained from Dharmacon as Non-TARGET \#2 siCONTROL (Cat\# D-001208-14-20). Cells were harvested after 96h incubation.

5′-aza-deoxycytidine (5′-aza-dC) treatment {#S16}
------------------------------------------

Cells (6 × 10^5^ cells/100 mm dish) were seeded in 10% FCS in corresponding media. After 24 h the cells were treated with 2.5 μM 5′-aza-dC (Sigma-Aldrich). Cells were harvested after 120h incubation and used for both RNA extraction and Western Blot assays.

Bisulfite sequencing of genomic DNA {#S17}
-----------------------------------

Bisulfite-converted genomic DNA was used as a template to amplify fragments of 220--351 bp with a high CpG content from around the TSS of *GPX1*. Primers designed using the MethPrimer software (<http://www.urogene.org/methprimer/:>), were GPX1_L1 AGGGAGTTTAGGTTTATAGGTTTTT GPX1_R1 TAACCTCCCCTTACAATACTTATTC; GPX1_L2 AGTATTGTAAGGGGAGGTTAGTAGG and GPX1_R2 AATTACCTAAACCAAACCAAACATAC. Amplified PCR fragments were sequenced directly.

Gel-Shift Assay {#S18}
---------------

Gel Shift Assay Core System (Cat\# E3050, Promega) was used, a 60bp probe (NCBI36/hg18 chr3:49,370,821-49,370,881) was labeled and TFAP2C protein was generated from pcDNA3.1-AP2C ([@R52]) using TNT T7 Quick Coupled Transcription/Translation System Cat\#L1170 (Promega). Cold double stranded competitors were made as follows (possible binding sites are underlined): GPX1_5 CAGTTTTCCGG[GCCTGAGGG]{.ul}, GPX1_6 TCCCGCCTCATCCGGCCCCC, GPX1_7 GCCCTA[CCCGGAGGG]{.ul}CTCGG, and GPX1_5\* TTCCGG[GCCTGAGGG]{.ul}TCCCG. 2 μg Abs AP-2γ (6E4/4) (Santa Cruz Biotechnology) were added per reaction as needed.

GPX Activity Assay {#S19}
------------------

The activity of GPX1 was conducted using Glutathione Peroxidase Cellular Activity Assay Kit Cat\# CPG1 (Sigma-Aldrich).

Tert-butyl-OOH sensitivity Assay {#S20}
--------------------------------

The tert-butyl hydroperoxide assay was performed as described with slight modifications ([@R53]). BT-474 were transfected in 6-well dishes with either NT or TFAP2C siRNA for 48 hours as described above. MCF-7 cells were seeded in 6-well dishes and transduced with 100 MOI of adenovirus harboring wild-type human TFAP2C, wild-type human GPX-1, or empty vector (all vectors obtained from the Gene Transfer Vector Core Facility, University of Iowa) and allowed to incubate for 24 hours. Treated cells were trypsinized and seeded into 96-well plates at approximately 10^4^ cells/well. Following overnight incubation, cells were exposed to varying concentrations of tert-butyl hydroperoxide in phenol red- and serum-free DMEM (MCF-7) or Optimem (BT-474) for 24 hours. Media was removed and replaced with media containing 0.5 mg/ml MTT, and incubated for 3 hours at 37° C. This media was replaced with 50 ul of DMSO to solubilize the formazan crystals, and absorbance was read on a Tecan Infinite 200 plate reader at 570 nm with a reference of 630 nm.
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![Expression of TFAP2C and ChIP-seq in Breast Cancer Lines\
**A.** Western blots of cell lines shown demonstrate expression pattern for ERα, HER2, TFAP2C and TFAP2A. **B.** ChIP-seq data for TFAP2C genomic binding in breast cancer cell lines with the genome browser graphical output for the *KRT8* and *GPX1* genes. The y-axis represents normalized coverage (reads per million mapped) for all four cell lines with *KRT8* and *GPX1* presented to the same scale. **C.** Oncomine data of expression (log2 scale) of GPX1 in primary breast cancers.](nihms394886f1){#F1}

![GPX1 Expression and TFAP2C regulation\
**A.** GPX1 expression by RT-PCR (top panel) and Western blot (bottom panels) in four breast cancer cell lines. **B.** GPX1 expression in BT-474 and MDA-MB-453 after transfection with siRNAs: Mock (mock transfected), non-targeting (NT), TFAP2A (A) or TFAP2C (C) or both siRNAs (A+C). **C.** The 60 bp region of the *GPX1* gene promoter with consensus sequences of potential AP-2 binding sites (underlined) and relative location of additional oligonucleotide competitors used in gel-shift assay. **D**. Gel shift with radiolabeled probe shown in C with oligo competitors. The locations of free probe, TFAP2C complex and complex supershift are noted.](nihms394886f2){#F2}

![GPX Activity and Sensitivity to tert-butyl hydroperoxide\
**A.** Selenium-dependent GPX activity in four breast cancer cell lines demonstrated significantly greater activity in BT-474 and MDA-MB-453 compared to MCF-7 and SKBR-3. B. Sensitivity to tert-butyl hydroperoxide was measured at various concentrations comparing BT-474 transfected with siRNA to TFAP2C (siTFAP2C) or a non-targeting siRNA (siNT) and demonstrates increased drug sensitivity with knock down of TFAP2C over a concentration range of 20 to 60 μM. **C.** Selenium-dependent GPX activity was induced in MCF-7 cells by overexpression of GPX1 by infection with Ad-GPX1 (G) compared to Ad-empty (E) or Ad-TFAP2C (C), p\<0.05. Western blots below graph confirm expression of proteins after viral infection. **D.** Sensitivity to tert-butyl hydroperoxide was measured at various concentrations comparing MCF-7 cells infected with adenoviruses indicated demonstrating that overexpression of GPX1 significantly increased resistance to tert-butyl hydroperoxide at concentrations of 40 μM and above.](nihms394886f3){#F3}

![Methylation of *GPX1* promoter\
**A.** Results of bisulphite sequencing of CpG island of *GPX1* promoter in cell lines shown with CpGs denoted by a circle. **B.** Example of sequencing reads from the *GPX1* promoter CpG island from template prepared from MCF-7 and BT-474 cells demonstrating the presence of C preceding a G in the site indicated by arrows showed that these cytosines were methylated in MCF-7 cells. Unmethylated cytosines (C) were converted to uracils (T) in BT-474 cells. **C.** Expression of GPX1 by RT-PCR (top panel) and Western blot (bottom panels) after treatment with 5-aza dC for cell lines shown. **D.** ChIP analysis performed with anti-TFAP2C antibody compared to IgG at *GPX1* promoter demonstrated significant increase in binding of TFAP2C after treatment with 5-aza-dC, whereas, no evidence for binding of TFAP2C in absence of drug (Mock). Data normalized to ChIP with IgG.](nihms394886f4){#F4}

![Methylation of *GPX1* gene and expression of GPX1, TFAP2A and TFAP2C in primary breast cancer samples\
**A.** Examples of results from bisulfite sequencing demonstrating the methylation patterns among primary breast cancer samples showing high degree of methylated ([@R1]--[@R4]) and unmethylated ([@R5]--[@R8]) chromatin. **B/C.** Semi-quantitative RT-PCR used to determine a correlation between GPX1 expression and expression of TFAP2A (**B**) and TFAP2C (**C**) in panel of primary breast cancer samples (n=20). Results demonstrated strong association between expression of TFAP2C and GPX1 in unmethylated samples with R^2^= 0.908, p\<0.0001. No significant correlation was found comparing GPX1 expression with TFAP2A expression with R^2^=0.022, p=0.58.](nihms394886f5){#F5}
